The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis

The Experience of Vaccination of a Patient With Juvenile Idiopathic Arthritis With Frequent Respiratory Infections With a Pneumococcal 13-Valent Conjugate Vaccine During Methotrexate Therapy

“…[29] с участием 63 детей с ЮИА. Первая группа (n=31) получала инги-битор фактора некроза опухоли альфа, вторая (n=32) -метотрексат.…”

Pneumococcal Vaccination of Patients with Juvenile Idiopathic Arthritis: Review of International Experience

“…с участием 63 детей с ЮИА. Первая группа (n = 31) получала ингибитор TNF ␣, во второй (n = 32) -проводили стандартную противоревматическую терапию [28]. После введения первой дозы ПКВ7 в обеих группах средние геометрические титры всех серотипов вакцины были значительно увеличены.…”

Current information about vaccination practice in pediatric rheumatic diseases and recommendations for future applications

“…43 Most studies supported the safety and immunogenicity of PPV and PCV vaccines in pediatric patients with RD. 12,30,44 The responses to 7-valent pneumococcal conjugate vaccine was investigated in one study. Significantly lower antibody concentrations to three serotypes were found in patients on anti-TNFα treatment.…”